Monday, September 1, 2014   

Janssen raises alarm on drug in Japan after 17 deaths
(04-09 19:18)

The Japanese unit of drug maker Janssen Pharmaceuticals says 17 people have died after being injected with its drug to treat schizophrenia.
Fatalities have piled up since the drug was launched in Japan last November.
The company, an affiliate of US-based Johnson and Johnson, advised medical workers to use the Paliperidone Palmitate medication with great care even though it was not known whether it had caused the deaths.
The drug, named Xeplion, is estimated to have been used by 10,700 people since November 19, according to a web notice.
The causes of the 17 deaths included cardiac infarction, pulmonary embolism and suffocation due to inhalation of vomit.
In many cases the deaths occurred about 40 days after injections of the drug.—AFP
   
Other World breaking news:
Parents of UK boy with tumor face Spanish hearing (1 hr 12 mins ago)
Americans detained in North Korea call for US help (1 hr 19 mins ago)
Japan firm showcases 'touchable' 3D technology (1 hr 26 mins ago)
UK to propose anti-terror laws (2 hrs 5 mins ago)
Japan launches campaign to stockpile toilet paper (2 hrs 27 mins ago)
19 new dengue cases in Japan, linked to Tokyo park (2 hrs 29 mins ago)
Gunman kills two in New Zealand govt office (09-01 15:50)
German train drivers plan walkout (09-01 15:48)
Two dead in New Zealand welfare office shooting (09-01 15:20)
Japan says electronics OK during take-off and landing (09-01 14:28)

More breaking news >>

© 2014 The Standard, The Standard Newspapers Publishing Ltd.
Contact Us | About Us | Newsfeeds | Subscriptions | Print Ad. | Online Ad. | Street Pts

 


Home | Top News | Local | Business | China | ViewPoint | CityTalk | World | Sports | People | Central Station | Spree | Features

The Standard

Trademark and Copyright Notice: Copyright 2014, The Standard Newspaper Publishing Ltd., and its related entities. All rights reserved.  Use in whole or part of this site's content is prohibited.   Use of this Web site assumes acceptance of the
Terms of Use, Privacy Policy Statement and Copyright Policy.  Please also read our Ethics Statement.